Form 4: Estrella Immunopharma CEO Reports Stock Transaction
Insider Transaction (Form 4)
Cheng Liu, CEO and a Director of Estrella Immunopharma, Inc., reported multiple transactions in common stock on August 25, 2026.
Summary
- Option exercise/conversion: acquired 100,000 Common Stock, par value $0.0001 per share at $0.81 ($81,500) on August 25, 2026; holds 397,437 after (Direct).
- Option exercise/conversion: acquired 100,000 Incentive Stock Option on August 25, 2026; holds 900,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Cheng Liu — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-25 | Option exercise/conversion | Common Stock, par value $0.0001 per share | 100,000 | $1 | $81.5K | 397,437 |
| 2026-08-25 | Option exercise/conversion | Incentive Stock Option | 100,000 | — | — | 900,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-25 | Option exercise/conversion (100,000 shares) |
| 2026-08-25 | Option exercise/conversion (100,000 shares) |
Keywords
insider transaction, Form 4, ESLA, Estrella Immunopharma, Inc., neutral, Cheng Liu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.